Prevention and treatment of nonpostmenopausal osteoporosis

被引:19
作者
Hansen, LB
Vondracek, SF
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Clin Pharm & Family Med, Denver, CO 80262 USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Clin Pharm, Denver, CO 80262 USA
关键词
adolescents; anorexia netvosa; anticoagulants; anticonvulsants; antineoplastic agents; costs; heparin; hyperthyroidism; inflammatory bowel diseases; lung diseases; methotrexate; osteoporosis; postmenopause; quality of life; steroids; cortico-; toxicity; transplantation; warfarin;
D O I
10.1093/ajhp/61.24.2637
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The causes, prevention, and treatment of osteoporosis in specific populations are discussed. Summary. Osteoporosis and osteopenia affect 44 million women and men ages 50 years or older. Fractures are the most devastating consequence of this disease and significantly affect quality of life, activities of daily living, survival, and health care costs. Most osteoporosis research has focused on postmenopausal women, but several other populations are at risk for osteoporosis, such as patients taking certain medications that affect bone health and those with various health conditions that cause bone loss, including anorexia nervosa, hyperthyroidism, organ transplantation, chronic obstructive pulmonary disease, and inflammatory bowel disease. Glucocorticoids are the most common secondary cause of osteoporosis. Other medications that have been implicated as secondary causes include anticonvulsants, heparin, warfarin, and methotrexate. Preventing osteoporosis may be even more important in adolescence than after menopause. Conclusion. Osteoporosis needs to be recognized, monitored, and appropriately treated in patients taking medications that affect bone health and in patients with conditions that increase the risk of osteoporosis.
引用
收藏
页码:2637 / 2654
页数:18
相关论文
共 208 条
[31]  
2-P
[32]  
Baker SS, 1999, PEDIATRICS, V104, P1152, DOI 10.1542/peds.104.5.1152
[33]   A prospective, controlled study of the effects of hormonal contraception on bone mineral density [J].
Berenson, AB ;
Radecki, CM ;
Grady, JJ ;
Rickert, VI ;
Thomas, A .
OBSTETRICS AND GYNECOLOGY, 2001, 98 (04) :576-582
[34]   Prevention of osteoporosis in heart transplant recipients: A comparison of calcitriol with calcitonin and pamidronate [J].
Bianda, T ;
Linka, A ;
Junga, G ;
Brunner, H ;
Steinert, H ;
Kiowski, W ;
Schmid, C .
CALCIFIED TISSUE INTERNATIONAL, 2000, 67 (02) :116-121
[35]   COPD and osteoporosis [J].
Biskobing, DM .
CHEST, 2002, 121 (02) :609-620
[36]   CRITICAL YEARS AND STAGES OF PUBERTY FOR SPINAL AND FEMORAL BONE MASS ACCUMULATION DURING ADOLESCENCE [J].
BONJOUR, JP ;
THEINTZ, G ;
BUCHS, B ;
SLOSMAN, D ;
RIZZOLI, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (03) :555-563
[37]   Bone mineral density in children and adolescents: Relation to puberty, calcium intake, and physical activity [J].
Boot, AM ;
deRidder, MAJ ;
Pols, HAP ;
Krenning, EP ;
KeizerSchrama, SMPFD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (01) :57-62
[38]   Primary prevention of gluccocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone [J].
Boutsen, Y ;
Jamart, J ;
Esselinckx, W ;
Devogelaer, JP .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (01) :104-112
[39]   Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial [J].
Boutsen, Y ;
Jamart, J ;
Esselinckx, W ;
Stoffel, M ;
Devogelaer, JP .
CALCIFIED TISSUE INTERNATIONAL, 1997, 61 (04) :266-271
[40]  
Brown JP, 2002, CAN MED ASSOC J, V167, pS1